中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.031 seconds)

    Development of Injectable Fiducial Markers for Image Guided Radiotherapy with Dual MRI and CT Visibility
    2.
    发明申请
    Development of Injectable Fiducial Markers for Image Guided Radiotherapy with Dual MRI and CT Visibility 审中-公开

    公开(公告)号：US20200222560A1

    公开(公告)日：2020-07-16

    申请号：US16615504

    申请日：2018-05-24

    Applicant: TECHNICAL UNIVERSITY OF DENMARK ,  NANOVI RADIOTHERAPY APS

    Inventor： Thomas Andresen ,  Rasmus Irming Jølck ,  Linda Maria Bruun

    IPC: A61K49/10 ,  A61K49/08 ,  A61K49/12 ,  A61K9/00 ,  A61K47/26

    Abstract: Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1:1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable T1 contrast enhancement (T1˜0.900 ms) in the rim over at least 3 weeks with clinically observable resolution.

    Development of injectable fiducial markers for image guided radiotherapy with dual MRI and CT visibility
    3.
    发明授权
    Development of injectable fiducial markers for image guided radiotherapy with dual MRI and CT visibility 有权

    公开(公告)号：US11331396B2

    公开(公告)日：2022-05-17

    申请号：US16615504

    申请日：2018-05-24

    Applicant: TECHNICAL UNIVERSITY OF DENMARK ,  NANOVI RADIOTHERAPY APS

    Inventor： Thomas Andresen ,  Rasmus Irming Jølck ,  Linda Maria Bruun

    IPC: A61K49/10 ,  A61K49/08 ,  A61K9/00 ,  A61K47/26 ,  A61K49/12

    Abstract: Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1:1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable T1 contrast enhancement (T1˜900 ms) in the rim over at least 3 weeks with clinically observable resolution.

    Palpable marker composition
    5.
    发明授权
    Palpable marker composition 有权

    公开(公告)号：US11058780B2

    公开(公告)日：2021-07-13

    申请号：US16302517

    申请日：2017-05-19

    Applicant: TECHNICAL UNIVERSITY OF DENMARK ,  NANOVI RADIOTHERAPY APS

    Inventor： Thomas Lars Andresen ,  Rasmus Irming Jølck ,  Linda Maria Bruun

    IPC: A61K49/00 ,  A61K9/00 ,  A61K47/26

    Abstract: The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body. In another embodiment the composition is a liquid before administration and has the ability to transform into a crystalline or amorphous solid after administration.

    PALPABLE MARKER COMPOSITION
    6.
    发明申请
    PALPABLE MARKER COMPOSITION 审中-公开

    公开(公告)号：US20190275174A1

    公开(公告)日：2019-09-12

    申请号：US16302517

    申请日：2017-05-19

    Applicant: TECHNICAL UNIVERSITY OF DENMARK ,  NANOVI RADIOTHERAPY APS

    Inventor： Thomas Lars Andresen ,  Rasmus Irming Jølck ,  Linda Maria Bruun

    IPC: A61K49/00 ,  A61K9/00

    Abstract: The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body. In another embodiment the composition is a liquid before administration and has the ability to transform into a crystalline or amorphous solid after administration.

Patent Agency Ranking